Adaptive Biotechnologies (NASDAQ:ADPT) and AlloVir (NASDAQ:ALVR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability and risk.
Analyst Recommendations
This is a summary of current ratings and target prices for Adaptive Biotechnologies and AlloVir, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Adaptive Biotechnologies | 0 | 2 | 4 | 0 | 2.67 |
AlloVir | 0 | 0 | 4 | 0 | 3.00 |
Adaptive Biotechnologies currently has a consensus price target of $61.40, indicating a potential upside of 52.85%. AlloVir has a consensus price target of $48.75, indicating a potential upside of 114.19%. Given AlloVir's stronger consensus rating and higher probable upside, analysts clearly believe AlloVir is more favorable than Adaptive Biotechnologies.
Institutional and Insider Ownership
80.8% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 32.1% of AlloVir shares are owned by institutional investors. 22.2% of Adaptive Biotechnologies shares are owned by insiders. Comparatively, 1.0% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Adaptive Biotechnologies and AlloVir's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Adaptive Biotechnologies | -132.32% | -20.15% | -13.09% |
AlloVir | N/A | N/A | N/A |
Earnings & Valuation
This table compares Adaptive Biotechnologies and AlloVir's revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Adaptive Biotechnologies | $85.07 million | 65.74 | $-68,610,000.00 | ($1.01) | -39.77 |
AlloVir | N/A | N/A | N/A | N/A | N/A |
AlloVir has lower revenue, but higher earnings than Adaptive Biotechnologies.
Summary
AlloVir beats Adaptive Biotechnologies on 5 of the 8 factors compared between the two stocks.